AWM
ITRM

Avior Wealth Management’s Iterum Therapeutics ITRM Stock Holding History

Avior Wealth Management’s Portfolio ITRM Stock Details ITRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-13
Closed -$23 – 1535
2024
Q4 		$23 Hold
13
– – ﹤0.01% 2437
2024
Q3 		$14 Buy
+13
New +$15 ﹤0.01% 2298

Other funds holding ITRM

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
AF
Apollon Financial Mount Pleasant, South Carolina $848M AUM 27.31% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $11.8B AUM 21.23% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $2.1B AUM 23.1% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
SA
Sanctuary Advisors Indianapolis, Indiana $21.6B AUM 28.31% 1-Year Est. Return
LF
Lee Financial Dallas, Texas $783M AUM 23.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return

Avior Wealth Management's ITRM Position: Q1 2025 in Review

Avior Wealth Management sold out of Iterum Therapeutics (ITRM) in Q1 2025, closing a stake of 13 shares — an estimated $23 sold.

Avior Wealth Management first reported a position in ITRM in Q3 2024 and held it in 2 quarters. The position peaked at $23 in Q4 2024. 20 funds tracked by Wall St. Rank hold ITRM as of Q1 2025.

  • Avior Wealth Management reported no remaining Iterum Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Avior Wealth Management sold 13 Iterum Therapeutics shares in Q1 2025, an estimated $23.
  • Avior Wealth Management first reported a position in Iterum Therapeutics in Q3 2024 and held it in 2 quarters.
  • Avior Wealth Management's Iterum Therapeutics position peaked at $23 in Q4 2024.
  • 20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q1 2025.

Based on Avior Wealth Management's 13F filing for Q1 2025, filed 21 Apr 2025.